The most significant development in the Monsanto Roundup litigation is the U.S. Supreme Court’s January 16, 2026 announcement that it will review *Durnell v. Monsanto*, a case that could determine the fate of more than 60,000 active cancer claims against Bayer. The central question before the Court is whether federal pesticide labeling law preempts state-based failure-to-warn claims””a ruling in Bayer’s favor could effectively end thousands of pending lawsuits, while a ruling for plaintiffs would allow the litigation to continue. A decision is expected by June 2026.
The financial stakes are enormous. Bayer has already paid approximately $11 billion in Roundup settlements to resolve roughly 100,000 claims, with average individual payouts around $160,000. Yet approximately 61,000 lawsuits remain active nationwide, and since October 2023, plaintiffs have secured eight consecutive trial victories totaling over $6 billion in verdicts. The company added another $1.37 billion to its litigation reserves in August 2025, bringing total funds set aside for Roundup litigation to more than $16 billion. This article examines the Supreme Court case and its potential implications, breaks down the current litigation statistics, reviews recent verdicts and settlement values, and explains what plaintiffs should understand about the legal landscape heading into 2026.
Table of Contents
- What Is the Latest News on the Monsanto Roundup Lawsuit in 2026?
- Current Roundup Litigation by the Numbers
- Recent Verdicts Show Continued Plaintiff Success at Trial
- Roundup Settlement Values and What Plaintiffs Can Expect
- Federal Preemption: The Legal Question That Could End Thousands of Cases
- Legislative Efforts to Limit Roundup Lawsuits Have Stalled
- What Happens After the Supreme Court Rules in June 2026
- Conclusion
What Is the Latest News on the Monsanto Roundup Lawsuit in 2026?
The headline development is the Supreme Court’s decision to take up the federal preemption question that has divided lower courts. The Ninth Circuit has allowed state failure-to-warn claims to proceed against Monsanto, reasoning that federal labeling requirements under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) do not prevent states from requiring additional warnings. The Eleventh Circuit reached the opposite conclusion, ruling that FIFRA preempts such claims because the EPA approved glyphosate’s labeling. This circuit split created legal uncertainty that the Supreme Court will now resolve.
If the Court sides with Bayer, plaintiffs in states across the country could see their claims dismissed on preemption grounds, regardless of the scientific evidence they might present. If the Court rules for plaintiffs, the existing litigation framework would remain intact, and trials would continue to focus on whether Monsanto adequately warned consumers about cancer risks associated with Roundup. For context, consider the practical difference: a plaintiff in California (Ninth Circuit) currently has a viable path to trial, while a similarly situated plaintiff in Georgia (Eleventh Circuit) faces an uphill battle. The Supreme Court’s ruling will create a uniform national standard, but which standard remains to be seen.
Current Roundup Litigation by the Numbers
The scale of Roundup litigation is staggering. Approximately 170,000 total claims have been filed against Monsanto and its parent company Bayer. Of those, roughly 100,000 have been settled, leaving about 61,000 active lawsuits pending nationwide as of January 2026. Within the federal court system, 4,511 open cases remain consolidated in the multidistrict litigation (MDL) in the Northern District of California.
These numbers represent one of the largest mass tort litigations in American history, comparable to asbestos and tobacco litigation in scope. However, unlike those earlier mass torts, the Roundup litigation developed rapidly””most claims were filed within a decade, following a 2015 determination by the International Agency for Research on Cancer that glyphosate is “probably carcinogenic to humans.” It is worth noting that the remaining 61,000 cases do not guarantee 61,000 eventual payouts. Some claims may be dismissed on procedural grounds, others may fail to establish causation, and the Supreme Court decision could eliminate a significant portion depending on how broadly preemption applies. Plaintiffs with pending claims should understand that the litigation remains dynamic and outcomes are far from certain.
Recent Verdicts Show Continued Plaintiff Success at Trial
Despite Bayer’s legal setbacks, plaintiffs have won every trial that has gone to verdict since October 2023″”eight consecutive wins totaling more than $6 billion. The most notable recent verdict included $65 million in compensatory damages and $2 billion in punitive damages, though punitive awards of this magnitude are typically reduced on appeal or through post-trial motions. In a significant appellate development, the Missouri Court of Appeals for the Western District affirmed a $611 million verdict for three plaintiffs. This ruling is notable because appellate affirmance suggests the verdict was supported by sufficient evidence and free from reversible legal error””a meaningful signal for other pending cases.
However, verdicts and actual payouts are different things. Large punitive damage awards are frequently reduced to satisfy constitutional proportionality requirements, and appeals can take years to resolve. A plaintiff who wins a $100 million verdict at trial may ultimately collect a fraction of that amount after post-trial litigation concludes. The $611 million Missouri affirmance is encouraging for plaintiffs, but each case turns on its specific facts and procedural history.
Roundup Settlement Values and What Plaintiffs Can Expect
Bayer’s $11 billion in settlements breaks down into approximately $9.6 billion for resolved claims and $1.25 billion reserved for future lawsuits. Individual settlement amounts have ranged from $5,000 to $250,000, with an average payout around $160,000. These figures reflect the wide variation in case strength, injury severity, and other factors that influence settlement valuations. The range is important to understand. A plaintiff with non-Hodgkin lymphoma who used Roundup extensively for decades and has strong documentation may receive a settlement toward the higher end of the range.
A plaintiff with weaker causation evidence or a less severe diagnosis may receive substantially less. Settlement programs typically tier claims based on factors like cancer type, duration of exposure, age, and strength of medical evidence. The tradeoff between settling and proceeding to trial is significant. Settlements provide certainty and faster resolution””plaintiffs receive compensation without the risk of losing at trial or waiting years for appeals to conclude. Trial offers the possibility of larger awards but carries substantial risk, including the chance of receiving nothing if the jury finds for Bayer or if an appellate court reverses a favorable verdict.
Federal Preemption: The Legal Question That Could End Thousands of Cases
The preemption issue at the heart of *Durnell v. Monsanto* is technical but consequential. FIFRA requires EPA approval of pesticide labels, and Bayer argues that once the EPA approves a label without a cancer warning, federal law “preempts” (blocks) state tort claims alleging the company should have included such a warning. Plaintiffs counter that FIFRA does not prevent states from holding manufacturers liable for failure to warn about known risks. If the Supreme Court adopts Bayer’s position, the implications extend beyond Roundup.
A broad preemption ruling could shield manufacturers of other EPA-regulated pesticides from similar state-law claims, fundamentally reshaping the landscape of pesticide litigation. Conversely, a narrow ruling””or one favoring plaintiffs””would preserve the current system where juries evaluate whether manufacturers met their duty to warn consumers. One limitation plaintiffs should understand: even if the Supreme Court rules against preemption, individual cases must still prove that glyphosate caused their specific cancer and that a warning would have changed their behavior. Preemption is a threshold legal issue, not a determination of liability. Winning on preemption simply keeps the courthouse door open””it does not guarantee victory.
Legislative Efforts to Limit Roundup Lawsuits Have Stalled
Beyond the courts, Bayer has pursued legislative solutions to its litigation problem. The company backed legislation in Congress that would have limited failure-to-warn lawsuits for EPA-approved pesticides.
As of January 2026, that legislation has stalled in the House, though a proposed 2026 appropriations bill could potentially strengthen Bayer’s federal preemption argument through different means. This legislative track illustrates how mass tort defendants often fight on multiple fronts simultaneously””in trial courts, appellate courts, the Supreme Court, and Congress. For plaintiffs, it means the legal landscape can shift not only through judicial decisions but also through legislative action that may receive less public attention.
What Happens After the Supreme Court Rules in June 2026
The Supreme Court’s decision will set the course for Roundup litigation for years to come. If the Court rules for Bayer, many pending claims could be dismissed, though the specific scope would depend on the reasoning of the opinion. Some claims might survive under narrower theories of liability that do not depend on failure-to-warn allegations.
If the Court rules for plaintiffs, expect continued settlements and trials. Bayer would face pressure to resolve the remaining 61,000 cases, and the company’s August 2025 addition of $1.37 billion to litigation reserves suggests it is preparing for that possibility. Either way, the June 2026 decision will provide clarity after years of conflicting lower court rulings””though for many plaintiffs, the wait continues.
Conclusion
The Monsanto Roundup litigation enters 2026 at a critical juncture. The Supreme Court’s review of *Durnell v. Monsanto* will resolve the federal preemption question that has split circuit courts, potentially determining whether tens of thousands of cancer claims can proceed.
With approximately 61,000 active lawsuits, $11 billion already paid in settlements, and eight consecutive plaintiff verdicts since October 2023, the stakes for both sides are substantial. Plaintiffs with pending claims or those considering filing should monitor the Supreme Court’s proceedings closely and consult with qualified legal counsel about how different outcomes might affect their cases. The June 2026 decision will not end this litigation entirely, but it will establish the legal framework that governs it going forward.